Stay updated with breaking news from Fair bond value. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharming Group N.V.: Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
18.04.2024 - NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond . ....
CELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion Erik Gatenholm, CEO Phone (Sweden): +46 70 991 86 04 Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138 Email: eg@cellink.com Email: gd@cellink.com This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 01.30 CET on 12 March 2021. About CELLINK Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researcher ....
Cellink AB announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion Erik Gatenholm, CEO Phone (Sweden): +46 70 991 86 04 Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138 Email: eg@cellink.com Email: gd@cellink.com This is information that Cellink is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 17.50 CET on 11 March 2021. About Cellink Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to c ....